NCT03350295View on ClinicalTrials.gov

Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2018

Primary Completion Date

September 18, 2018

Study Completion Date

December 14, 2018

Conditions

Chagas Disease

Interventions

DRUG

Nifurtimox (Lampit, BAYA2502)

Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E

Trial Locations (1)

C1425BAB

FP Clinical Pharma, Buenos Aires